Skip to main content
Top
Published in: Journal of General Internal Medicine 3/2021

01-03-2021 | Addiction | History of Medicine

Societal Biases, Institutional Discrimination, and Trends in Opioid Use in the USA

Authors: Danielle R. Fine, MD, MSc, David Herzberg, PhD, Sarah E. Wakeman, MD

Published in: Journal of General Internal Medicine | Issue 3/2021

Login to get access

Abstract

History has demonstrated cyclical trends in opioid use in the USA, alternating between high rates of prescribing driven by compassion and marketing and restrictive prescribing driven by stigma and fear of precipitating addiction and other harms. Two under-recognized yet powerful forces driving these trends are societal biases against individuals who use and are addicted to drugs, as well as a recognized social determinant of health, institutional discrimination. In the context of these influential forces, which are often based on racist and classist ideologies, we examine the history of opioid use in the USA from the 1800s when the vast majority of those addicted to opioids were middle- to upper-class women to the present-day white-washed narrative of the opioid crisis. As the demographics of those affected by opioid use and addiction has started to shift from white communities to communities of color, we cannot allow the preliminary success observed in white communities to obscure rising mortality rates from opioids in black and Latinx communities. To do so, we highlight ways to prevent racist and classist ideologies from further shaping responses towards opioid use. It is important to acknowledge the long history that has influenced responses to opioid use in the USA and take active steps towards promoting a sense of compassion towards all individuals who use and those who are addicted to drugs.
Literature
2.
go back to reference Courtwright DT. Dark Paradise: Opiate addiction in America before 1940. Cambridge, MA: Harvard University Press; 1982. Courtwright DT. Dark Paradise: Opiate addiction in America before 1940. Cambridge, MA: Harvard University Press; 1982.
3.
go back to reference Fernandez H, Libby TA. Heroin: Its history, pharmacology, and treatment. 2nd ed. Center City, MN: Hazelden; 2011. Fernandez H, Libby TA. Heroin: Its history, pharmacology, and treatment. 2nd ed. Center City, MN: Hazelden; 2011.
4.
go back to reference Gabriel JM. Restricting the sale of “deadly poisons”. Pharmacists, drug regulation, and narratives of suffering in the Gilded Age. Pharm Hist. 2011;53(1):29-45.PubMed Gabriel JM. Restricting the sale of “deadly poisons”. Pharmacists, drug regulation, and narratives of suffering in the Gilded Age. Pharm Hist. 2011;53(1):29-45.PubMed
5.
go back to reference Herzberg D. White Market Drugs: Big Pharma and The Hidden History of Addiction in America. Chicago University Press; 2020. Herzberg D. White Market Drugs: Big Pharma and The Hidden History of Addiction in America. Chicago University Press; 2020.
6.
go back to reference Acker C. Creating the American junkie: addiction research in the classic era of narcotic control. Baltimore, MD: Johns Hopkins University Press; 2002. Acker C. Creating the American junkie: addiction research in the classic era of narcotic control. Baltimore, MD: Johns Hopkins University Press; 2002.
7.
go back to reference Herzberg D. Entitled to Addiction?: Pharmaceuticals, Race, and America’s First Drug War. Bull Hist Med. 2017;91(3):586-623.CrossRef Herzberg D. Entitled to Addiction?: Pharmaceuticals, Race, and America’s First Drug War. Bull Hist Med. 2017;91(3):586-623.CrossRef
8.
go back to reference Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821-826.CrossRef Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821-826.CrossRef
9.
go back to reference Courtwright DT. The Controlled Substances Act: how a “big tent” reform became a punitive drug law. Drug Alcohol Depend. 2004;76(1):9-15.CrossRef Courtwright DT. The Controlled Substances Act: how a “big tent” reform became a punitive drug law. Drug Alcohol Depend. 2004;76(1):9-15.CrossRef
10.
go back to reference Hansen H, Netherland, J. Is the Prescription Opioid Epidemic a White Problem? Am J Public Health. 2016;106(12):2127-2129.CrossRef Hansen H, Netherland, J. Is the Prescription Opioid Epidemic a White Problem? Am J Public Health. 2016;106(12):2127-2129.CrossRef
11.
go back to reference Palamar JJ, Davies S, Ompad DC, Cleland CM, Weitzman M. Powder Cocaine and Crack Use in the United States: An Examination of Risk for Arrest and Socioeconomic Disparities in Use. Drug Alcohol Depend. 2015;149:108-116.CrossRef Palamar JJ, Davies S, Ompad DC, Cleland CM, Weitzman M. Powder Cocaine and Crack Use in the United States: An Examination of Risk for Arrest and Socioeconomic Disparities in Use. Drug Alcohol Depend. 2015;149:108-116.CrossRef
12.
go back to reference Netherland J, Hansen, H. White opioids: Pharmaceutical race and the war on drugs that wasn’t. Biosocieties. 2017;12(2):217-238.CrossRef Netherland J, Hansen, H. White opioids: Pharmaceutical race and the war on drugs that wasn’t. Biosocieties. 2017;12(2):217-238.CrossRef
13.
go back to reference Mauer M. The Crisis of the Young African American Male and the Criminal Justice System. Washington, D.C.: The Sentencing Project; 1999. Mauer M. The Crisis of the Young African American Male and the Criminal Justice System. Washington, D.C.: The Sentencing Project; 1999.
14.
go back to reference Mauer M, Huling, T. Young Black Americans and the Criminal Justice System: Five Years Later. Washington, D.C.: The Sentencing Project; 1995. Mauer M, Huling, T. Young Black Americans and the Criminal Justice System: Five Years Later. Washington, D.C.: The Sentencing Project; 1995.
15.
go back to reference Lembke A. Drug Dealer, MD. Baltimore, MD: Johns Hopkins University Press; 2016. Lembke A. Drug Dealer, MD. Baltimore, MD: Johns Hopkins University Press; 2016.
16.
go back to reference Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221-227.CrossRef Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221-227.CrossRef
17.
go back to reference Government Accounting Organization. OxyContin abuse and diversion and efforts to address the problem: highlights of a government report. J Pain Palliat Care Pharmacother. 2004;18(3):109-113. Government Accounting Organization. OxyContin abuse and diversion and efforts to address the problem: highlights of a government report. J Pain Palliat Care Pharmacother. 2004;18(3):109-113.
19.
go back to reference Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. The journal of pain : official journal of the American Pain Society. 2009;10(12):1187-1204.CrossRef Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. The journal of pain : official journal of the American Pain Society. 2009;10(12):1187-1204.CrossRef
20.
go back to reference Olsen Y, Daumit, Gail L., Ford, Daniel E. Opioid Prescriptions by U.S. Primary Care Physicians From 1992 to 2001. The Journal of Pain. 2006;7(4):225-235. Olsen Y, Daumit, Gail L., Ford, Daniel E. Opioid Prescriptions by U.S. Primary Care Physicians From 1992 to 2001. The Journal of Pain. 2006;7(4):225-235.
21.
go back to reference Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. Jama. 2008;299(1):70-78.CrossRef Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. Jama. 2008;299(1):70-78.CrossRef
22.
go back to reference Friedman J, Kim D, Schneberk T, et al. Assessment of Racial/Ethnic and Income Disparities in the Prescription of Opioids and Other Controlled Medications in California. JAMA Intern Med. 2019. Friedman J, Kim D, Schneberk T, et al. Assessment of Racial/Ethnic and Income Disparities in the Prescription of Opioids and Other Controlled Medications in California. JAMA Intern Med. 2019.
23.
go back to reference Gaither JR, Gordon K, Crystal S, Edelman EJ, Kerns RD, Justice AC, Fiellin DA, Becker WC. Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug Alcohol Depend. 2018;0(0). Gaither JR, Gordon K, Crystal S, Edelman EJ, Kerns RD, Justice AC, Fiellin DA, Becker WC. Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug Alcohol Depend. 2018;0(0).
26.
go back to reference Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug and Alcohol Dependence. 2016;164:14-21.CrossRef Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug and Alcohol Dependence. 2016;164:14-21.CrossRef
27.
go back to reference Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine Treatment Divide by Race/Ethnicity and Payment. JAMA Psychiatry. 2019. Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine Treatment Divide by Race/Ethnicity and Payment. JAMA Psychiatry. 2019.
28.
go back to reference Wilson N KM, Seth P, Smith H IV, Davis NL. Drug and Opioid-Involved Overdose Deaths — United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69:290-297.CrossRef Wilson N KM, Seth P, Smith H IV, Davis NL. Drug and Opioid-Involved Overdose Deaths — United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69:290-297.CrossRef
31.
go back to reference James K, Jordan A. The Opioid Crisis in Black Communities. J Law Med Ethics. 2018;46(2):404-421.CrossRef James K, Jordan A. The Opioid Crisis in Black Communities. J Law Med Ethics. 2018;46(2):404-421.CrossRef
32.
go back to reference Tesema L, Marshall J, Hathaway R, et al. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors. Subst Abus. 2018;39(4):434-440.CrossRef Tesema L, Marshall J, Hathaway R, et al. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors. Subst Abus. 2018;39(4):434-440.CrossRef
33.
go back to reference Haffajee RL, Bohnert ASB, Lagisetty PA. Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230-S242.CrossRef Haffajee RL, Bohnert ASB, Lagisetty PA. Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230-S242.CrossRef
34.
go back to reference Finley EP, Garcia A, Rosen K, McGeary D, Pugh MJ, Potter JS. Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res. 2017;17(1):420.CrossRef Finley EP, Garcia A, Rosen K, McGeary D, Pugh MJ, Potter JS. Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res. 2017;17(1):420.CrossRef
35.
go back to reference Bao Y, Pan Y, Taylor A, et al. Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians. Health Aff (Millwood). 2016;35(6):1045-1051.CrossRef Bao Y, Pan Y, Taylor A, et al. Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians. Health Aff (Millwood). 2016;35(6):1045-1051.CrossRef
Metadata
Title
Societal Biases, Institutional Discrimination, and Trends in Opioid Use in the USA
Authors
Danielle R. Fine, MD, MSc
David Herzberg, PhD
Sarah E. Wakeman, MD
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 3/2021
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-05974-0

Other articles of this Issue 3/2021

Journal of General Internal Medicine 3/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.